2021年ADA美國糖尿病學會年會-SOLIMIX STUDY

2021年第81屆ADA（美國糖尿病學會）發表了SOLIMIX STUDY主要是基礎胰島素和腸泌素（GLP-1 RA）的複方製劑（iGlarLixi）與預混胰島素的隨機對照試驗(RCT)。

直接講結論：一天一次的基礎胰島素和腸泌素複方針劑對比於一天二次的長短效預混胰島素，有比較好的血糖控制，更少的體重增加，更少的低血糖事件。一天一次的頻率也較一天二次有更好的醫囑順從性及病人操作方便性。

原文如下：Conclusions: Once-daily iGlarLixi provided better glycemic control with weight benefit and less hypoglycemia than twice-daily premix BIAsp 30. iGlarLixi is a more efficacious, simpler, and well-tolerated alternative to premix BIAsp 30 in suboptimally controlled type 2 diabetes requiring treatment beyond basal insulin plus OAD therapy.

Reference: Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled